AVTX
Overvalued by 94.9% based on the discounted cash flow analysis.
Market cap | $9.92 Million |
---|---|
Enterprise Value | $-100,259,693.00 |
Dividend Yield | $0.0 (0.0%) |
Earnings per Share | $-0.51 |
Beta | 0.0 |
Outstanding Shares | 1,034,130 |
Avg 30 Day Volume | 66,390 |
Return on Equity | - |
---|---|
Return on Assets | - |
Return on Invested Capital | - |
P/E Ratio | -0.07 |
---|---|
PEG | -0.01 |
Price to Sales | 9.59 |
Price to Book Ratio | -0.1 |
Enterprise Value to Revenue | -69.19 |
Enterprise Value to EBIT | 5.04 |
Enterprise Value to Net Income | 0 |
Total Debt to Enterprise | 0 |
Debt to Equity | 0 |
No data
No data
Cerecor is a biopharmaceutical company focused on becoming a leader in the development and commercialization of treatments for rare and orphan diseases. The company is advancing its clinical-stage pipeline of innovative therapies that ad...